NCT06800313 - A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 24, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions

Prostate Cancer Metastatic DiseaseProstate Cancer (Adenocarcinoma)

Interventions

DRUG

HLD-0915

A treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

Trial Locations (11)

10065

RECRUITING

Evelyn H. Lauder Breast and Imaging Center (BAIC), New York

29572

RECRUITING

Carolina Urologic Research Center, LLC, Myrtle Beach

34232

RECRUITING

Florida Cancer Specialists, Sarasota

37203

RECRUITING

SCRI Oncology Partners, Nashville

49546

RECRUITING

START Midwest, LLC, Grand Rapids

77030

RECRUITING

The University of Texas M.D. Anderson Cancer Center, Houston

78758

RECRUITING

NEXT Austin, Austin

80218

RECRUITING

Sarah Cannon Research Institute at HealthONE, Denver

06520

RECRUITING

Yale - New Haven Hospital - Yale Cancer Center, New Haven

02114

RECRUITING

Massachusetts General Hospital, Boston

SM2 5PT

RECRUITING

Royal Marsden Hospital, Sutton